Vast has formed a strategic partnership with Cedars-Sinai to advance microgravity science and crew health aboard the upcoming Haven-1 commercial space station, scheduled for launch in 2027. This collaboration will focus on stem cell and organoid research, alongside biomanufacturing technology demonstrations, aimed at enhancing regenerative medicine, longevity, and disease modeling in microgravity environments.